Recommendation
This article presents recommendations developed by the Atopic Dermatitis Group of the Portuguese Society of Dermatology and Venereology addressing several clinical questions that arise in the management and care of moderate-tosevere atopic dermatitis with biologic agents and Janus kinase inhibitors based on the available evidence.
Review
This review summarizes the clinical data available from various trials and reports on the safety and efficacy of abrocitinib, baricitinib, and upadacitinib, the three oral systemic JAK inhibitors used in the treatment of atopic dermatitis.
Review
This article reviews the therapeutic landscape in myelofibrosis, which has
significantly improved, and emerging drugs with different
target pathways, alone or in combination with ruxolitinib.
promising.